Evidence map›Paper›PMID 28631076›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2018

Effects of Glycyrrhizic Acid on the Pharmacokinetics of Pristimerin in Rats and its Potential Mechanism.

Xiufen Zhao, Yan Wu, Dongmei Wang

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Pharmaceutical biology · 2020
    Article
  3. Pharmaceutical biology · 2020
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Xiufen ZhaoDepartment of Obstetrics and Gynecology, Qingdao Hiser Medical Group, Qingdao, 266033, Shandong, China.
Yan WuDepartment of Obstetrics and Gynecology, Qingdao Hiser Medical Group, Qingdao, 266033, Shandong, China. yan_wu12@163.com.
Dongmei WangDepartment of Obstetrics and Gynecology, Qingdao Hiser Medical Group, Qingdao, 266033, Shandong, China.
Haier Group (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesPristimerin has been reported to possess a wide range of pharmacological activities. This study investigates the effects of glycyrrhizic acid on the pharmacokinetics of pristimerin in rats.

methodsThe pharmacokinetics of orally administered pristimerin (2 mg/kg) with or without glycyrrhizic acid pretreatment (at a dose of 100 mg/kg/day for 7 days) were investigated. The plasma concentration of pristimerin was determined using a sensitive and reliable LC-MS/MS method, and the pharmacokinetics profiles were calculated and compared. Additionally, Caco-2 cell transwell model and rat liver microsome incubation experiments were also conducted to investigate its potential mechanism.

resultsThe results showed that when the rats were pretreated with glycyrrhizic acid, the maximum concentration (C

conclusionsIn conclusion, these results indicated that glycyrrhizic acid could affect the pharmacokinetics of pristimerin, and it might work through decreasing the absorption of pristimerin by inducing the activity of P-gp or through increasing the clearance rate in rat liver by inducing the activity of cytochrome P450 enzyme.

Indexed as

AnimalsBiological TransportCells, CulturedDrug InteractionsGlycyrrhizic AcidMaleMicrosomes, LiverPentacyclic TriterpenesRatsTriterpenescelastrolGlycyrrhizic AcidPentacyclic TriterpenesTriterpenes

Identifiers

PMID28631076
OpenAlexW2631706350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.